Infliximab (IFX), a monoclonal antibody inhibiting anti‐tumour necrosis factor (TNF), is a widely used biologic therapy whose originator (Remicade®) was the first biologic drug approved for the treatment of inflammatory bowel disease (IBD) in 1998.1 Here, TNF is linked to inflammatory bowel disease.